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Abstract
Mi(cro)RNAs are small non-coding RNAs of 18-25 nucleotides in length that modulate gene expression at the post-
transcriptional level. These RNAs have been shown to be involved in a several biological processes, human diseases and
metabolic disorders. Proanthocyanidins, which are the most abundant polyphenol class in the human diet, have positive
health effects on a variety of metabolic disorders such as inflammation, obesity, diabetes and insulin resistance. The present
study aimed to evaluate whether proanthocyanidin-rich natural extracts modulate miRNA expression. Using microarray
analysisandQ-PCR,weinvestigatedmiRNAexpressioninHepG2cellstreatedwith proanthocyanidins. Ourresultsshowedthat
when HepG2 cells were treated with grape seed proanthocyanidin extract (GSPE), cocoa proanthocyanidin extract (CPE) or
pure epigallocatechin gallate isolated from green tea (EGCG), fifteen, six and five differentially expressed miRNAs, respectively,
were identified out of 904 mRNAs. Specifically, miR-30b* was downregulated by the three treatments, and treatment with
GSPE or CPE upregulated miR-1224-3p, miR-197 and miR-532-3p. Therefore, these results provide evidence of the capacity of
dietary proanthocyanidins to influence microRNA expression, suggesting a new mechanism of action of proanthocyanidins.
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Introduction
MicroRNAs (miRNAs) are small non-coding RNAs of 18-25
nucleotides in length that bind to complementary 39UTR regions
of target mRNAs, inducing the degradation or transcriptional
repression of the target [1]. A single miRNA can regulate the
expression of multiple target mRNAs [2]. To date, more than
15000 miRNAs have been recorded in the miRBase database
(www.mirbase.org/, April 2011), and it is thought that these tiny
molecules may regulate approximately 30% of all cell transcripts
[3,4]. miRNAs have been reported to regulate several metabolic
pathways such as insulin secretion, cholesterol biosynthesis and
triglyceride, carbohydrate and lipid metabolism [5,6,7]. In
addition, miRNAs have been shown to be involved in other
biological processes such as differentiation and development [8].
Furthermore, not only have miRNAs be shown to be related to
several human diseases, there is also evidence that the modulation
of miRNAs can provide therapeutic benefits [9,10,11]. Interest-
ingly, dietary factors, including micronutrients and non-nutrient
dietary components, have been shown to alter miRNA gene
expression [12]. For instance, dietary polyphenols such as soy
isoflavones [13] and the green tea polyphenol epigallocatechin
gallate [13,14] have been shown to modulate miRNA expression.
More than 8000 phenolic structures have been reported in plants,
and many of them occur in food [15]. Interestingly, the phenolic
compositions of food plants differ considerably between sources, and
several databases are emerging that provide quantitative informa-
tion on the phenol content of foods. These databases include the
USDA [16] and Phenol-Explorer databases. Proanthocyanidins are
the most abundant polyphenols in the human diet, mainly provided
by fruits, beans, nuts, cocoa, tea and wine [15,17]. Proanthocya-
nidins have been shown to play important roles in several biological
processes resulting in health benefits. For instance, proanthocyani-
dins have been reported to have antioxidant, anti-inflammatory,
antimicrobial, antiproliferative, cardioprotective, hypolipidemic and
antidiabetic activities [17,18,19].
Different proanthocyanidin extracts have been studied to
determine their health and biochemical effects. Among them,
grape seed proanthocyanidin extract (GSPE) and cocoa proantho-
cyanidin extract (CPE) have been used extensively. Proanthocya-
nidin extracts contain a broad range of different molecular
structures characteristic of their botanical origin. Both GSPE and
CPE can range in molecular weight from monomers to long-chain
polymers. However, GSPE is mainly composed of trimeric
proanthocyanidins [20], whereas CPE primarily contains dimeric
proanthocyanidins [21]. Moreover, GSPE contains considerable
amounts of galloylated monomers, such as epicatechin gallate and
epigallocatechin gallate [20], whereas CPE contains little amounts
of epigallocatechin [21]. Differences in the chemical structures of
the proanthocyanidins present in the extract, such as the degree of
polymerization and/or the presence of galloyl moieties, have been
demonstrated to be important for proanthocyanidin functions
[22,23,24]. For example, galloylated polyphenols have been shown
to have greater inhibitory effects than non-galloylated polyphenols
on pancreatic lipase [22].
Because polyphenols exhibit potent free radical-scavenging
properties, it was thought that polyphenols have beneficial health
effects by acting as antioxidants. However, it is now evident that
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cellular signaling cascades and gene expression [15,18]. As
miRNAs have been reported to regulate several metabolic
pathways [6], the objective of this study was to identify potential
miRNA targets of proanthocyanidins in hepatocytes to identify
new molecular mechanisms of action of these polyphenols.
Proanthocyanidin extracts contain a broad range of different
molecular structures characteristic of their botanical origin. For
this reason, we used two different proanthocyanidin extracts
(GSPE and CPE) and pure epigallocatechin gallate (EGCG) to
determine which miRNA is the most universal target of
proanthocyanidins. miR-1224-3p, miR-197 and miR-532-3p were
differentially expressed after treatment with the two procyanidin
extracts; however, only miR-30b* was differentially expressed in
response to all the three treatments. Four hundred and eighty gene
targets for miR-30b* have been validated, some of which are
central to lipid and glucose metabolism, insulin signaling, oxidative
stress and inflammation. All of these processes have been suggested
to be responsible for the health effects of proanthocyanidin
consumption.
Results
miRNA expression profiles in HepG2 cells treated with
proanthocyanidin extracts or EGCG
To evaluate the capacity of proanthocyanidins to modify
miRNA expression, all human miRNAs were screened in human
hepatocellular carcinoma (HepG2) cells. HepG2 cells were
treated for 5 h with 100 mg/L of grape seed or cacao
proanthocyanidin extracts or with 50 mg/L of EGCG. GSPE
and CPE were selected because they have different molecular
compositions [20,21] and are known to have beneficial health
effects on metabolic disorders. Moreover, EGCG was selected
because it is present in GSPE but not in CPE [20,21]. Two
biological samples for each treatment were analyzed by micro-
arrays, and differentially expressed miRNAs were identified by
using raw p value a filter based on statistical significance (P,0.05)
as calculated by the Limma (Bioconductor) test due to the small
sample size.
EGCG and the two procyanidin extracts modulated miRNA
expression in HepG2 cells compared to the control cells. GSPE
treatment (Table 1) differentially upregulated the expression of
nine miRNAs and repressed the expression of six miRNA, whereas
CPE treatment (Table 2) differentially repressed the expression of
three miRNAs and upregulated the expression of three other
miRNAs. Finally, EGCG treatment differentially repressed the
expression of five miRNAs. These results indicated that the wide
variety of molecular structures present in the extracts controlled
the expression of a greater number of miRNAs compared to pure
EGCG. Moreover, GSPE had a greater miRNA-modulation effect
than CPE.
To validate the microarray results, two miRNAs (miR-1224-
3p and miR-30b*) were selected for QRT-PCR quantification.
Two biological samples for each treatment were analyzed by
QRT-PCR. The selected miRNA expression levels obtained by
Q-PCR were similar to those observed by microarray analysis
(Tables 1, 2 and 3). Therefore, these results validated the
microarray analysis.
Interestingly, miR-30b* was repressed by all three treatments.
No other overlaps were observed for EGCG and CPE, whereas
both GSPE and EGCG treatments repressed miR-453. On the
other hand, the two procyanidin extracts upregulated the
expression of miR-1224-3p, miR-197 and miR-532-3p. These
show that the cacao and grape seed proanthocyanidin extracts
were more similar to each other than to EGCG.
Identification of the target genes of the differentially
expressed miRNAs using bioinformatics analysis
For further analysis of the results, bioinformatics studies were
performed to identify the target genes of the differentially
expressed miRNAs. We focused our attention on miR-30b*
because it was the only miRNA affected by the three treatments.
The miRWalk online database (http://www.umm.uni-heidelberg.
de/apps/zmf/mirwalk/) contained 480 genes that have been
experimentally verified as target genes of miR-30b*. In addition to
Table 1. miRNAs differentially expressed in HepG2 cells after
5 hours of culture with grape seed proanthocyanidin extract.
miRNA
Chromosome
localization Fold change P Value
upregulated
has-miR-1224-3p 3q27.1 2.67 (2.83 6 0.29) 0.000
has-miR-449b* 5q11.2 1.83 0.004
has-miR-197 1p13.3 1.68 0.009
has-miR-1249 22q13.31 1.54 0.020
has-miR-1234 8q24.3 1.49 0.020
has-miR-532-3p Xp11.23 1.28 0.045
has-miR-15b* 3q25.33 1.27 0.041
has-miR-522 19q13.42 1.25 0.045
has-miR-744* 17p12 1.24 0.049
downregulated
has-miR-2110 10q25.3 21.25 0.045
has-miR-483-5p 11p15.5 21.29 0.043
has-miR-320c 18q11.2 21.32 0.040
has-miR-453 14q32.31 21.43 0.022
has-miR-1290 1p36.13 21.45 0.021
has-miR-30b* 8q24.22 22.01 (21.14 6 0.17) 0.002
The fold change value and the standard deviations obtained by QRT-PCR is
presented in parentheses.
doi:10.1371/journal.pone.0025982.t001
Table 2. miRNAs differentially expressed in HepG2 cells after
5 hours of culture with cocoa proanthocyanidin extract.
miRNA
Chromosome
localization Fold change P Value
upregulated
has-miR-197 1p13.3 1.48 0.016
has-miR-1224-3p 3q27.1 1.36 (3.59 6 0.74) 0.028
has-miR-532-3p Xp11.23 1.29 0.036
downregulated
has-miR-765 1q23.1 21.25 0.043
has-miR-187* 18q12.2 21.23 0.046
has-miR-30b* 8q24.22 21.48 (20.18 6 0.25) 0.016
The fold change value and the standard deviations obtained by QRT-PCR is
presented in parentheses.
doi:10.1371/journal.pone.0025982.t002
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beneficial effects related to lipid and glucose metabolism, insulin
signaling, oxidative stress and inflammation. Therefore, we
focused our attention on miR-30b* target genes related to these
pathways using the miRWalk, BioCarta and KEGG databases
(Table 4). Interestingly, this bioinformatics investigation revealed
validated target genes belonging to the following pathways:
inflammation pathway (BioCarta), NK-kappa-B pathway (Bio-
Carta), Peroxisome proliferators-activated receptors PPAR signal-
ing pathway (KEGG), PPARA pathway (BioCarta), insulin
pathway (BioCarta), insulin signaling pathway (KEGG), glycolysis
and gluconeogenesis (KEGG), glycerolipid metabolism (KEGG),
mitochondria pathway (BioCarta), oxidative phosphorylation
(KEGG) and glutathione metabolism (KEGG).
The miRWalk database also contains experimentally validated
target genes for the additional three miRNAs (miR-1224-3p,
miR-197 and miR-532-3p) that were differentially overexpressed
in response to both proanthocyanidin extracts (Table 5), although
the number of target genes for these miRNAs was much lower
than for miR-30b*. The miRWalk database lists validated target
genes independent of their organ and tissue. Thus, in the liver
context in which we performed our studies, the significant
validated genes for these miRNAs are related to transcription
factors (RUNX3, MYC), proteolysis (BRCA1 and CAPNS1),
inflammation (NFKB1 and RELB) and fatty acid synthesis
(FASN).
The estrogen receptor alpha (ESR1) was the only target gene
validated for miR-453 (Table 6) that was differentially expressed in
response to GSPE and EGCG.
Discussion
In this study, we investigated the effect of dietary proanthocya-
nidins on miRNA expression to identify potential miRNA targets
of proanthocyanidins. To achieve this goal, we selected the
HepG2 human hepatoma cell line because dietary proanthocya-
nidins have been reported to reach the liver at high levels [25].
Moreover, hepatocytes have the enzymatic machinery to metab-
olize these compounds (glucuronidation, sulfation and methyla-
tion). We used two proanthocyanidin extracts (GSPE and CPE)
with different compositions in addition to pure EGCG to search
for a universal proanthocyanidin target miRNA. This study was
conducted shortly after treatment (five hours) because we were
searching for miRNAs that are able to act as primary mediators
that trigger the effects of proanthocyanidins on cell functionality
and metabolism. Previous results have showed that in vivo changes
in mRNA levels related to lipid metabolism occur after 5 hours of
GSPE treatment [26].
As shown in Tables 1 and 2, proanthocyanidins induced up to
2.67-fold changes. These values were expected because food
compounds, in contrast to drugs, normally induce low levels of
gene expression changes. Interestingly, GSPE was more effective
than CPE with respect to modulating miRNA expression,
probably due to the different chemical compositions. This result
suggests that each proanthocyanidin may influence particular
miRNAs. Proanthocyanidins can have a variety of structures that
include different (i) chain lengths (this is known as the degree of
polymerization), (ii) hydroxylation patterns, (iii) stereochemistries
at the three chiral centers and (iv) locations and types of
interflavan linkage [27]. Furthermore, the characteristic compo-
sition of an extract varies based on its botanical origin, the
growing conditions of the cultivar and processing [15].
Therefore, we hypothesized that a specific proanthocyanidin,
or a specific interaction between compounds, may affect a
miRNA specifically.
On the other hand, HepG2 treatment with the monomeric
EGCG was less successful in modifying miRNA expression.
Several studies have focused their attention on the effect of the
degree of polymerization on the biological activity of proantho-
cyanidins. For instance, the oxidation-inhibiting power of
polymerized oligomers is much stronger than that of monomers
[28]. The monomeric and dimeric structures do not reproduce
the bioactivity of GSPE in glucose and lipid metabolism and only
act as anti-inflammatory agents [29]. In contrast, a trimeric-
enriched fraction of GSPE reproduces all of the biological effects
of GSPE [29]. Thus, EGCG could affect fewer miRNA because
of its low polymerization degree. Moreover, EGCG has more
similarities to GSPE than to CPE. Gallate derivatives of
proanthocyanidins are more abundant in GSPE than in CPE
[20], in which only traces of epigallocatechin, and not EGCG,
have been found [21].
Other authors have studied the influence of EGCG on the
expression levels of miRNAs in HepG2 cells [14]. However, there
was no overlap between the miRNAs differentially expressed in
response to EGCG in the work of Tsang and Kwok [14] and those
in the present study. This discrepancy could be explained by the
different periods of treatment and the different doses: our miRNA
experiments were performed after 5 hours of treatment with a dose
of 50 mM, whereas in [14], the treatment was performed for 24
hours with a dose of 100 mM.
Interestingly, miR-30b*, the sole miRNA affected by the two
proanthocyanidin extracts and EGCG, is the miRNA among
those differentially expressed in response to proanthocyanidins
that has the greatest number of validated target genes. To our
knowledge, no paper has been published regarding the specific
role of has-miR-30b* in intracellular processes. On the other
hand, 480 target genes of miR-30b* have been experimentally
verified. These target genes are implicated in numerous cell
pathways, ranging from cell signaling to metabolism. Proantho-
cyanidins exert health benefits by improving lipid metabolism
[18], glucose metabolism and insulin sensitivity [30] and by
reducing inflammation [31,32] and oxidative stress [33]. The
target genes of has-miR-30b* are included in pathways involved in
these processes. Thus, miR-30b* likely mediates part of the
beneficial health effects of proanthocyanidins.
Proanthocyanidins induce a strong hypotriglyceridemic effect
in experimental animals [18], in part by inhibiting VLDL
secretion by the liver [34,35]. miR-122 and miR-33, among
others, play major roles in regulating cholesterol and fatty acid
homeostasis in the liver [36]; however, neither of these miRNAs
Table 3. miRNAs differentially expressed in HepG2 cells after
5 hours of culture with epigallocatechin gallate.
miRNA
Chromosome
localization Fold change P Value
downregulated
has-miR-30b* 8q24.22 21.56 (21.03 6 0.94) 0.037
has-miR-453 14q32.31 21.33 0.041
has-miR-520-e 19q13.42 21.33 0.038
has-miR-629 15q23 21.25 0.045
has-miR-608 10q24.31 21.88 0.046
The fold change value and the standard deviations obtained by QRT-PCR is
presented in parentheses.
doi:10.1371/journal.pone.0025982.t003
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ments. However, fatty acid synthase, which plays a central role in
liver lipogenesis [37], is a validated target gene of miR-197,
which was upregulated by both proanthocyanidin extracts. It has
been reported that oligomeric forms of proanthocyanidins
specifically control endogenous liver lipid production [29], in
accordance with the fact that miR-197 was only modulated by
the extracts.
As we indicated in the introduction, proanthocyanidin extracts
are a complex combination of different molecular structures.
Thus, several molecular mechanisms by which proanthocyanidins
modulate cell functionally have been described. It has been
demonstrated that grape seed procyanidin extract activates the
insulin receptor and key targets of insulin signaling pathways [30].
In addition, it has been shown that procyanidins decrease plasma
triglyceride levels by activating the nuclear receptor FXR,
Table 4. Selection of validated target genes for miR-30b* grouped by pathway.
Pathway Name
(1) Target gene
(2) Function of the encoded protein
(3)
Inflammation TGFB1 Member of the transforming growth factor beta (TGFB) family of cytokines.
PDGFA Member of the platelet-derived growth factor family.
IFNA1 Interferon alpha 1.
NF-kappa-B RELA Component of the NF-kappa-B complex.
IKBKB I-kappa-B protein kinase B. Allows activation of the NF-kappa-B complex.
PPAR signaling FADS2 Fatty acid desaturase. Desaturation of fatty acids.
LPL Lipoprotein lipase. Expressed in heart, muscle, and adipose tissue. Triglyceride hydrolase.
PDGFA Platelet-derived growth factor.
PTGS2 Cyclooxygenase. Key enzyme in prostaglandin biosynthesis.
RELA Component of the NF-kappa-B complex.
JUN jun proto-oncogene.
HSPA1A 70 kDa heat shock protein.
Insulin signaling JUN jun proto-oncogene.
PRKCI Protein kinase C iota.
PDE3A Cyclic nucleotide phosphodiesterase 3A. cGMP-inhibited.
IKBKB I-kappa-B protein kinase B. Allows activation of the NF-kappa-B complex.
GYS1 Glycogen synthase.
SOCS1 suppressor of cytokine signaling.
AKT1 Serine-threonine protein kinase.
RHEB Small GTPase, RAS-related.
PTPRF Protein tyrosine phosphatase, receptor type.
Glycolysis and Gluconeogenesis GAPDH Glyceraldehyde-3-phosphate dehydrogenase.
PGM1 Phosphoglucomutase 1.
Glycerolipid metabolism GPAM Glycerol-3-phosphate acyltransferase, mitochondrial. Catalyzes the initial and committing step in
glycerolipid biosynthesis. Pivotal role in the regulation of cellular triacylglycerol and phospholipid levels.
LPL Lipoprotein lipase. Expressed in heart, muscle, and adipose tissue. Triglyceride hydrolase.
LCLAT1 lysocardiolipin acyltransferase 1.
Mitochondria and Oxidative
phosphorylation
BCL2 Integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells.
ATP6V1C1 Component of vacuolar ATPase (V-ATPase).
ATP6V1F Component of vacuolar ATPase (V-ATPase).
ATP6V0A1 Component of vacuolar ATPase (V-ATPase).
COX8A Cytochrome c oxidase subunit VIIIA. Terminal enzyme of the respiratory chain.
Glutathione metabolism TXNDC12 Thioredoxin. Roles in redox regulation, defense against oxidative stress, refolding of disulfide-containing
proteins, and regulation of transcription factors.
IDH1 Isocitrate dehydrogenase 1 (NADP+), found in the cytoplasm and peroxisomes.
GSTM4 Glutathione S-transferase mu 4. Detoxification of electrophilic compounds, including carcinogens,
therapeutic drugs, environmental toxins and products of oxidative stress, by conjugation with
glutathione.
ANPEP Alanyl (membrane) aminopeptidase, Aminopeptidase N.
(1): from the KEGG (http://www.genome.jp/kegg/) and BioCarta (http://www.biocarta.com/) pathway databases.
(2): from the miRWalk database (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/).
(3): from the KEGG (http://www.genome.jp/kegg/) and NCBI-Gene (http://www.ncbi.nlm.nih.gov) databases.
doi:10.1371/journal.pone.0025982.t004
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subsequently repressing SREBP1 in the liver [34,35]. Moreover,
proanthocyanidins reduce inflammation by inhibiting the activa-
tion of NFkB [31]. Thus, the modulation of miRNA expression
may be an additional molecular mechanism by which proantho-
cyanidins, the most abundant polyphenols in the human diet,
could modulate cell functionality.
Materials and Methods
Reagents
EGCG ((-)-Epigallocatechin gallate) was purchased from Sigma-
Aldrich (Madrid, Spain), and GSPE (Grape Seed Procyanidin
Extract) was kindly provided by Les De ´rives Re ´siniques et
Terpe ´niques (Dax, France). This procyanidin extract contained
monomeric (10.1%), dimeric (12.3%), trimeric (77.1%) and
oligomeric (4–6 units) (less than 1%) procyanidins. CPE (cacao
procyanidin Extract) contained monomeric (27.8%), dimeric
(44.8%), trimeric (21.1%), tetrameric (5.3%), and oligomeric (5–
8 units) (1%) procyanidins.
Cells and cell culture
HepG2 human hepatocarcinoma cells were purchased from the
American Type Culture Collection (ATCC, LGC Promochen,
HB8065, Salisbury, United Kingdom). The cells were cultured
in Dulbecco’s Modified Eagle Medium (DMEM, Lonza, BE12-
614, Barcelona, Spain) supplemented with 10% fetal bovine serum
(Lonza, BE-14-802-F, Barcelona, Spain), 0.1 mM nonessential
amino acids (Sigma, M7145, Madrid, Spain), 100 U/ml penicillin
and 100 mg/ml streptomycin (Lonza, BE-17-602E, Barcelona,
Table 5. Validated target genes for the miRNAs differentially expressed in response to both grape seed and cocoa
proanthocyanidin extracts.
miRNA Target gene
(1) Function of the encoded protein
(2)
has-miR-1224-3p DROSHA ribonuclease type III. RNA maturation.
AMELX
CALB1 calbindin 1. Calcium metabolism.
EZH2 member of the Polycomb-group (PcG) family.
PRNP prion protein.
ENAM
TNF proinflammatory cytokine that belongs to the tumor necrosis factor superfamily.
has-miR-197 BRCA1 Type of ubiquitin ligase (E3). Ubiquitin-mediated proteolysis.
CAPNS1 Calpain, small subunit 1. Calcium-dependent cysteine proteases.
TUSC2
FUS component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complex, involved in pre-mRNA
splicing and the export of fully processed mRNA to the cytoplasm.
MYC Transcription factor. Plays a role in cell cycle progression, apoptosis and cellular transformation.
HMGA2 non-histone chromosomal high mobility group (HMG) protein family member; these protein function as
architectural factors and are essential components of the enhanceosome.
FASN fatty acid synthase. Catalyzes the synthesis of palmitate from acetyl-CoA.
TSPAN3 cell-surface protein. Mediates signal transduction events that play a role in the regulation of cell
development, activation, growth and motility.
IGF1 insulin-like growth factor 1 (somatomedin C).
EFEMP2 extracellular matrix protein.
IL6 interleukin 6 (interferon, beta 2).
ACVR1 activin A receptor.
NFKB1 This gene encodes a 105 kD protein that can undergo cotranslational processing by the 26S proteasome to
produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor, and the 50 kD
protein is the DNA-binding subunit of the NF-kappa-B (NFKB) protein complex.
RELB Component of the NF-kappa-B complex.
has-miR-532-3p RUNX3 Transcription factor.
CDKN2D cyclin-dependent kinase inhibitors.
(1): from the miRWalk database (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/).
(2): from the KEGG (http://www.genome.jp/kegg/) and NCBI-Gene (http://www.ncbi.nlm.nih.gov) databases.
doi:10.1371/journal.pone.0025982.t005
Table 6. Validated target genes for the miRNAs differentially
expressed in response to both grape seed proanthocyanidin
extract and epigallocatechin gallate.
miRNA Target gene
(1) Function of the encoded protein
(2)
has-miR-453 ESR1 Estrogen receptor alpha.
(1): from the miRWalk database (http://www.umm.uni-heidelberg.de/apps/zmf/
mirwalk/).
(2): from the KEGG (http://www.genome.jp/kegg/) and NCBI-Gene (http://www.
ncbi.nlm.nih.gov) databases.
doi:10.1371/journal.pone.0025982.t006
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and 25 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
(HEPES, Sigma, H3375, Madrid, Spain) in a humidified
incubator with 5% CO2 at 37uC.
miRNA microarray analysis
HepG2 cells were treated with 50 mg/L of EGCG, 100 mg/L
of GSPE or 100 mg/L of CPE dissolved in dimethyl sulfoxide
(DMSO, D8418, Sigma, Madrid, Spain), (final DMSO concen-
tration in growth media, 0.1%) for 5 h. For control samples
HepG2 cells were treated with 0.1% DMSO in growth media.
Total RNA was isolated using the miRNeasy Mini Kit (QIAGEN,
Izasa, Barcelona, Spain) following the manufacturer’s protocol.
For this analysis, febit’s ‘‘Geniom Biochip MPEA homo sapiens’’
biochip (febit biomed gmbh, Heidelberg, Germany) was used. The
probes were designed as the reverse complements of all major
mature miRNAs and the mature sequences as published in the
current Sanger miRBase release (version 14.0 September 2009,
http://microrna.sanger.ac.uk/sequences/index.shtml) for Homo
sapiens. Additional nucleotides were added to the 5’ end of each
capture oligonucleotide as necessary for the enzymatic extension in
the labeling procedure. The probes were synthesized with intra-
array replicates to increase the statistical confidence and to
compensate for potential positional effects. As a result, the raw
data files contained 7 data points for each miRNA. The intensities
of blank probes, which consisted only of one single ‘‘T’’ nucleotide,
were used for background corrections. Spike-in controls were also
performed for the labeling efficiency. To better control the
hybridization process and the positioning features, additional
hybridization controls were added to the array template. For each
array, the RNA was suspended in febit’s proprietary miRNA
Hybridization Buffer (25 ml per array, febit biomed gmbh,
Heidelberg, Germany). Hybridization was performed automati-
cally for 16 h at 42uC using a Geniom RTH-Analyzer (febit
biomed gmbh, Heidelberg, Germany). In the next step, the
biochip underwent a stringent wash. Following the labeling
procedure, febit ran a microfluidic-based primer extension assay.
This assay utilizes the bound miRNAs as a primer for an
enzymatic elongation with labeled nucleotides. The elongation was
performed with Klenow Fragments and biotinylated nucleotides at
37uC for 15 minutes. Finally, the biochip was washed automat-
ically. For maximum sensitivity, febit used Biotin-11-dATP
(PerkinElmer, Germany), which was detected with streptavidin-
phycoerythrin (SAPE), in combination with febit’s consecutive
Signal Enhancement (CSE) procedure. The feature recognition
(using Cy3 filter set) and signal calculation were performed
automatically within milliseconds.
Bioinformatics and statistical analysis
All bioinformatic and statistical analysis was provided by febit
(febit biomed gmbh, Heidelberg, Germany). Briefly, spatial effects
on the chip were investigated and corrected. Then, the intensity
value distribution of the raw data was analyzed and, if required,
normalized using variance stabilizing normalization (VSN). The
Limma test using Empirical Bayes Statistics was used for the
detection of differentially regulated miRNAs (raw p values , 0.05)
miRNA target prediction
miRNA target genes were identified using the miRWalk online
database (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/).
miRWalk provides information on published pathway targets from
the KEGG (http://www.genome.jp/kegg/) and BioCarta (http://
www.biocarta.com/) pathway databases. The functions of genes were
obtained from KEGG and NCBI-Gene (http://www.ncbi.nlm.nih.
gov).
Quantitative real-time PCR (qRT-PCR)
HepG2 cells were treated with 50 mg/L of EGCG, 100 mg/L
of GSPE or 100 mg/L of CPE dissolved in DMSO (D8418,
Sigma, Madrid, Spain), (final DMSO concentration in growth
media, 0.1%) for 5 h. For control samples HepG2 cells were
treated with 0.1% DMSO in growth media. Total RNA was
isolated using the miRNeasy Mini Kit (QIAGEN, Izasa,
Barcelona, Spain) following the manufacturer’s protocol. Two
biological replicates were used for the analysis. Total RNA (5 ng)
was reverse-transcribed using the TaqManH MicroRNA Reverse
Transcription kit (Applied Biosystems, Madrid, Spain) and the
miRNA-specific reverse-transcription primers provided with the
TaqManH MicroRNA Assay (Applied Biosystems, Madrid, Spain).
For the reverse-transcription, a My Gene L Series Peltier Thermal
Cycler (Long Gene, Madrid, Spain) was used. The reaction was
performed at 16uC for 30 min; 42uC for 30 min and 85uC for
5 min. The obtained miRNA-specific cDNA was amplified using
the TaqMan Universal PCR master mix (Applied Biosystems,
Madrid, Spain) and the respective specific probe provided in the
TaqManH MicroRNA Assay (Applied Biosystems, Madrid, Spain).
The targeted miRNA assay sequences were 59-CCCCACCUC-
CUCUCUCCUCAG-39 for miR-1224-3p and 59-CUGGGAG-
GUGGAUGUUUACUUC-39 for miR-30b*. PCR was per-
formed using a Real-Time 7300 PCR System (Applied
Biosystems, Madrid, Spain). Amplification was performed at
95uC for 10 min, followed by 40 cycles of 95uC for 15 s and
60uC for 1 min. U6 small nuclear RNA was used as an
endogenous control. The fold change in the miRNA level was
calculated by the log 2 scale of the equation 22DDCt, where DCt
= Ct miRNA-Ct U6 and DDCt= DCt treated samples- DCt
untreated controls.
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